Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Nafarelin 400 micrograms daily and danazol 600 mg daily were compared in a double-blind randomized study. Eighty-two patients with endometriosis were treated for 6 months after an initial laparoscopy and 74 had a second laparoscopy. Twenty-two (30%) patients had complete disease regression, 42 (57%) patients had a partial regression, and in 10 (13%) patients disease was unchanged or worse. Both treatments led to significant regression of active disease but not of adhesions. At 3 months follow-up, 34 (64%) patients reported their symptoms were improved, 15 (28%) reported no change, and 4 (8%) were worse. Nafarelin was associated with more hot flushes and headaches, and danazol with more weight gain. No significant differences, however, were noted in treatment efficacy between the two groups.

More information Original publication

DOI

10.1016/s0015-0282(16)53574-2

Type

Journal article

Publication Date

1990-06-01T00:00:00+00:00

Volume

53

Pages

998 - 1003

Total pages

5

Keywords

Adult, Amenorrhea, Analysis of Variance, Danazol, Double-Blind Method, Endometriosis, Estradiol, Female, Gonadotropin-Releasing Hormone, Humans, Nafarelin, Pregnadienes, Tissue Adhesions, Uterine Neoplasms